Unique Predictors of Mortality in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis in the REVEAL Registry

Chest

Volumn 146, Issue 6, 2014, Pages 1494-1504

  Chung, Lorinda ^a   Farber, Harrison W ^d   Benza, Raymond ^e   Miller, Dave P ^f   Parsons, Lori ^f   Hassoun, Paul M ^g   McGoon, Michael ^h   Nicolls, Mark R ^b   Zamanian, Roham T ^c  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ALLEGHENY GENERAL HOSPITAL   (United States)

^f ICON CLINICAL RESEARCH   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

6 MINUTE WALK DISTANCE; ADULT; AGE; ARTICLE; CONTROLLED STUDY; DIFFUSION CAPACITY OF THE LUNG FOR CARBON MONOXIDE; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HEART RIGHT ATRIUM PRESSURE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEW YORK HEART ASSOCIATION CLASS; PERICARDIAL EFFUSION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; REGISTER; RETROSPECTIVE STUDY; SEX; SURVIVAL RATE; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; ANALYSIS OF VARIANCE; CAUSE OF DEATH; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; HEART CATHETERIZATION; HYPERTENSION, PULMONARY; KAPLAN MEIER METHOD; MORTALITY; PREDICTIVE VALUE; RISK ASSESSMENT; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; SURVIVAL ANALYSIS;

AGE FACTORS; ANALYSIS OF VARIANCE; CARDIAC CATHETERIZATION; CAUSE OF DEATH; COHORT STUDIES; COMORBIDITY; FEMALE; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SURVIVAL ANALYSIS;

EID: 84987678141     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-3014     Document Type: Article

References (30)

1. 1 Hesselstrand, R, Wildt, M, Ekmehag, B, Wuttge, DM, Scheja, A, Survival in patients with pulmonary arterial hypertension associated with systemic sclerosis from a Swedish single centre: prognosis still poor and prediction difficult. Scand J Rheumatol 40:2 (2011), 127–132.
2. 2 Fisher, MR, Mathai, SC, Champion, HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 54:9 (2006), 3043–3050.
3. 3 Chung, L, Liu, J, Parsons, L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 138:6 (2010), 1383–1394.
4. 4 Rubenfire, M, Huffman, MD, Krishnan, S, Seibold, JR, Schiopu, E, McLaughlin, VV, Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era. Chest 144:4 (2013), 1282–1290.
5. 5 Condliffe, R, Kiely, DG, Peacock, AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 179:2 (2009), 151–157.
6. 6 Benza, RL, Miller, DP, Gomberg-Maitland, M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 122:2 (2010), 164–172.
7. 7 Humbert, M, Sitbon, O, Yaïci, A, et al. French Pulmonary Arterial Hypertension Network. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 36:3 (2010), 549–555.
8. 8 Ngian, GS, Stevens, W, Prior, D, et al. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther, 14(5), 2012, R213.
9. 9 Launay, D, Sitbon, O, Hachulla, E, et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis 72:12 (2013), 1940–1946.
10. 10 Chung, L, Domsic, RT, Lingala, B, et al. Survival and predictors of mortality in systemic sclerosis associated pulmonary arterial hypertension: outcomes from the PHAROS registry. Arthritis Care Res (Hoboken) 66:3 (2014), 489–495.
11. 11 McGoon, MD, Krichman, A, Farber, HW, et al. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc 83:8 (2008), 923–931.
12. 12 Simonneau, G, Robbins, IM, Beghetti, M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54:suppl 1 (2009), S43–S54.
13. 13 Badesch, DB, Raskob, GE, Elliott, CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 137:2 (2010), 376–387.
14. 14 Hankinson, JL, Odencrantz, JR, Fedan, KB, Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 159:1 (1999), 179–187.
15. 15 Lefèvre, G, Dauchet, L, Hachulla, E, et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum 65:9 (2013), 2412–2423.
16. 16 Mukerjee, D, St George, D, Coleiro, B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62:11 (2003), 1088–1093.
17. 17 Hachulla, E, Launay, D, Yaici, A, et al. French PAH-SSc Network. Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. Rheumatology (Oxford) 49:5 (2010), 940–944.
18. 18 Humbert, M, Yaici, A, de Groote, P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 63:11 (2011), 3522–3530.
19. 19 Campo, A, Mathai, SC, Le Pavec, J, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 182:2 (2010), 252–260.
20. 20 Khanna, PP, Furst, DE, Clements, PJ, Maranian, P, Indulkar, L, Khanna, D, D-Penicillamine Investigators. Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial. Rheumatology (Oxford) 49:5 (2010), 955–959.
21. 21 Avouac, J, Walker, U, Tyndall, A, et al. EUSTAR. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol 37:7 (2010), 1488–1501.
22. 22 Nagaya, N, Nishikimi, T, Uematsu, M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102:8 (2000), 865–870.
23. 23 Mathai, SC, Bueso, M, Hummers, LK, et al. Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J 35:1 (2010), 95–104.
24. 24 Williams, MH, Handler, CE, Akram, R, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 27:12 (2006), 1485–1494.
25. 25 Allanore, Y, Borderie, D, Avouac, J, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 58:1 (2008), 284–291.
26. 26 Thakkar, V, Stevens, WM, Prior, D, et al. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. Arthritis Res Ther, 14(3), 2012, R143.
27. 27 Coghlan, JG, Denton, CP, Grünig, E, et al. DETECT study group. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73:7 (2014), 1340–1349.
28. 28 Wensel, R, Opitz, CF, Anker, SD, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 106:3 (2002), 319–324.
29. 29 Campo, A, Mathai, SC, Le Pavec, J, et al. Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension. Eur Respir J 38:2 (2011), 359–367.
30. 30 Weng, HH, Ranganath, VK, Oh, M, et al. Differences in presentation of younger and older systemic sclerosis patients in clinical trials. Clin Exp Rheumatol 28:5 Suppl 62 (2010), S10–S14.